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Abstract. Mitochondrial transcription factors mtTFA, mtTFB1 and mtTFB2 are required for the replication of mitochondrial
DNA (mtDNA), regulating the number of mtDNA copies. Mice with a mtTFA deletion showed a reduced number of mtDNA
copies, a reduction in respiratory chain activity, and a characteristic dilated cardiomyopathy. DNA variants in these genes could
be involved in the risk for cardiac hypertrophy (HCM).
We determined the variation in the TFAM, TFB1M, and TFB2M genes (using SSCA, DHPLC, and direct sequencing) in a total
of 200 HCM-patients from Spain and Germany, and in 250 healthy controls. We found several common polymorphisms that
defined haplotype blocks in these genes, with frequencies that did not differ between patients and controls. We also found four
novel variants in patients which were absent in the controls: −91 C > A (5’-UTR) and Ala105 > Thr in TFAM, and Thr211 >
Ala and Arg256 > Lys in TFB1M. The three missense changes were in highly conserved amino acids, and could be involved in
HCM-risk.
In conclusion, common variants in the mitochondrial transcription factors were not associated with the risk for HCM. However,
rare DNA variants (putative mutations) could be involved in the pathogenesis of HCM in a reduced number of cases.
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1. Introduction
Mitochondria are the cellular organelles that gener-
ate energy as adenosine triphosphate (ATP). Mitochon-
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sespa.princast.es.
dria contain their own DNA (mtDNA) and their own
machinery for RNA and protein synthesis. The mito-
chondrial genome consists of 37 intronless genes, and
encodes 13 subunits of the electron-transfer chain, 2
ribosomal RNAs (rRNA), and 22 transfer RNAs (tR-
NA). However, most of the mitochondrial proteins are
encoded by genes in the nucleus and imported from the
cytoplasm. Expression of the mitochondrial genome is
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initiated in the D-loop regulatory region of the mtDNA,
and the basic transcription machinery consists of a mi-
tochondrial RNA (mtRNA) polymerase molecule, a mt
transcription factor A (mtTFA), and two related tran-
scription factors B1 and B2 (mtTFB1 and mtTFB2) [13,
15,37]. All these mitochondrial transcription factors
are encoded by nuclear genes, TFAM, TFB1M and
TFB2M. The mtTFBs interact with the C-terminal tail
of mtTFA, facilitating the interaction between the heavy
and light-strand promoters and the initiation of the tran-
scription [6,11]. In addition to its activity as a tran-
scription factor, mtTFB1 belongs to the family of RNA
adenine methyltransferases, a group of proteins that
methylate small subunit rRNAs at a conserved stem
loop [6].
Mutations in mtDNA are frequently linked to mul-
tisystemic diseases and follow a maternal transmission
(mitochondria are inherited from the mother), while
mutations in the nuclear genes encoding mitochondrial
proteins cause typical mendelian traits [2,10]. These
mtDNA mutations have an effect on cellular energy
metabolism, and more severely affect those organs that
are highly energy dependent, such as muscles and the
nervous system. Cardiac muscle contraction is high-
ly dependent on the energy supplied by mitochondria.
The accumulation of mtDNA deletions is responsible
for the age-related decrease in cardiac function, and
some mtDNA mutations have been linked to hyper-
trophic cardiomyopathy (HCM), either isolated or as
part of a multisystemic syndrome [19,21,33,40,41,44].
In addition to rare highly penetrant mutations, mtDNA
is highly polymorphic and some single nucleotide poly-
morphisms (SNPs) could contribute to the expression
of mitochondrial-related diseases [7,20].
Left ventricular hypertrophy(LVH) is caused by sev-
eral factors that impose overwork to the heart, such
as hypertension, valvular disease, cardiomyopathy, and
myocardial infarction [26,29,36]. Hypertrophic car-
diomyopathy (HCM) is the Mendelian autosomal dom-
inant form of LVH, and is primarily a disorder of the
cardiac sarcomere linked to mutations in genes that en-
code components of the sarcomere, although other non-
sarcomere genes could be involved in this disease [3,
4,30,38]. Thus, polymorphisms in the genes encoding
components of the renin-angiotensin and the endothe-
lin systems, among others, could be involved in the risk
of developing cardiac hypertrophy [5,8]. Further, some
authors have reported the association between mtDNA
variation and HCM [2,7,33].
Every cell contains hundreds of mitochondria, and
each mitochondriom about five mtDNA molecules.
The number of copies of mtDNA is directly dependent
on the levels of mtTFA [23,24]. Mice heterozygous
for a TFAM deletion showed a significant reduction in
mtDNA copies [28]. The overexpression of mtTFA in-
creased the number of copies, but did not affect respi-
ratory chain activity or mitochondrial mass [11]. Mice
with a deletion of TFAM limited to the heart repro-
duced the pathophysiological features of mitochondri-
al cardiomyopathy, and showed a significant reduction
of mtDNA copies in cardiomyocytes with a partial re-
duction in respitarory chain activity [27,42,43]. The
overexpression of mtTFB2 is accompanied by an in-
creased amount of mtDNA, while cells that overex-
pressed mtTFB1 showed significantly increased mito-
chondrial mass [9,12,31,43].
TFAM, TFB1M and TFB2M are thus candidate to
be involved in the risk for developing cardiac hypertro-
phy. Therefore, we searched for DNA variation in these
transcription factors in a cohort of well characterized
HCM patients, and analysed the association of puta-
tive mutations with the disease through a case-control
study.
2. Methods
2.1. Patients and controls
This study was part of a research to analyse the con-
tribution of DNA variation to HCM. A total of 150
patients with HCM were recruited at the Cardiology
Department of Hospital Central Asturias. The inclu-
sion criteria were a left ventricular wall thickness >
13 mm of unexplained cause: the hypertrophy was not
secondary to other cardiac diseases capable of produc-
ing LVH, such as hypertension, valvular disease, and
myocardial infarction. These patients were negative
for mutations in the most frequently mutated sarcom-
eric genes (MYH7, TNNT2, MYBPC3, TNNI2, and
TPM1). The main clinical and anthropometric charac-
teristics of the 150 patients are summarised in Table 1.
We also searched for TFAM, TFB1M, and TFB2M
variants in a cohort of 50 HCM patients from Germany
with the same clinical and genetic inclusion criteria as
the Spanish cohort.
A total of 250 healthy individuals, aged 20 to 75
years, were used as population controls for the genet-
ic association studies. These controls were recruited
through the blood bank and the Cardiology Dept. of
Hospital Central Asturias and did not have a history
of HCM. In 110 of these controls we performed elec-
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Table 1
Main characteristics of the 150 Spanish patients
Total 150
Male 90 (60%)
Age 47 ± 16 (20–65)
Family history of HCM 48 (32%)
Mean body mass index 27 ± 5
Mean LV septal thickness, mm 19 ± 6
range, mm 13–42
First clinical symptom
Dyspnea 95 (63%)
Arrhytmia 23 (15%)
Angina 32 (21%)
trocardiographic examination to exclude the existence
of HCM or other cardiovascular diseases; in 140 con-
trols, electro or echocardiographicstudies were not per-
formed to exclude the presence of asymptomatic LVH.
All the Spanish patients and controls were Caucasians
from the same region (Asturias, Northern Spain, total
population 1 million). All the individuals participating
in the study gave their informed consent, and the study
was approved by the Ethical Committee of Hospital
Central Asturias.
2.2. Genetic analysis of TFAM, TFB1M and TFB2M
Genomic DNA was obtained from 10 ml of blood,
and the coding regions of TFAM (7 exons), TFB1M
(7 exons), and TFB2M (8 exons) were PCR-amplified
in fragments 180 to 327 bp long. Each PCR consisted
of 100 ng of DNA, 2mM MgCl2, 2mM of each dNTP,
10 pmol of each primer pair, and 0.5 U of Taq DNA-
polymerase, in a final volume of 20 µl, and for a total
of 33 PCR cycles (30 s−95◦C, 60 s-annealing temper-
ature, 60 s −72◦C). Primer-sequences and PCR con-
ditions are available upon request to the correspond-
ing author. Nucleotide positions relative to the gene
sequences were numbered according to the Ensembl
database (www.ensembl.org). To search for sequence
variants, the PCR fragments were amplified from all
the patients and controls and analysed through single
strand conformation analysis (SSCA) and denaturing
high performance liquid chromatography (DHPLC).
For the SSCA, five µl of each PCR were mixed with
30 µl of formamide, denatured for 5 min at 95 ◦C, and
5 µl were loaded on a 6% SSCA-polyacrylamide gel
(5.8% acrylamide/0.2% bisacrylamide; 50 cm long).
After 18 h of electrophoresis at 25 W, gels were silver-
stained to visualise the electrophoretic patterns. For
the DHPLC analysis, the PCR-products were injected
in Helix DVB polymeric reversed-phase columns in a
Varian Helix system, and eluted with a linear binary
gradient created with buffers Varian Helix A (triethy-
lammonium amine – TEAA) and B (TEAA + 25% ace-
tonitrile) (www.varianinc.org). The DHPLC elution
temperatures and buffers gradient for the PCR frag-
ments were calculated with the DHPLC Melt Program
(http://insertion.stanford.edu/melt.html), and are avail-
able upon request to the corresponding author.
To identify the nucleotide changes responsible for
the observed genotypes, PCR fragments of cases repre-
sentative for the different electrophoretic patterns were
sequenced using BigDye chemistry in an automated
ABI310 capillary system (Applied Biosystems, Foster
City, CA, USA).
2.3. Genotyping, haplotypes and linkage
disequilibrium
Because each allele gaves a characteristic SSCA-
pattern, we could assign the genotype for each variant
in all the patients and controls. Allele and genotype
frequencies for the TFAM, TFB1M and TFB2M poly-
morphisms were determined in the Spanish patients and
controls by SSCA-genotyping.
The frequencies for all the possible haplotypes de-
fined by each pair of loci were calculated with the Cubic
exact solutions for the estimation of pairwise haplotype
frequencies (www.oege.org/software/cubex). This pro-
gramm estimates the haplotype frequencies, the nor-
malised linkage disequilibrium (LD) parameter (D’),
and the LD correlation coefficient between two loci
(r2) [17].
2.4. Statistical analysis
Allele and genotype frequencies in patients and con-
trols were compared through a chi-square test. Odds ra-
tios (OR) with 95% confidence intervals (CI) were ob-
tained to calculate the relative risk of HCM associated
with the genotypes. The Chi2 was also used to analyse
the deviation from the Hardy–Weinberg equilibrium of
the genotype frequencies. All statistical analyses were
performed with the SPSS statistical package (v.11.0).
3. Results
We searched for TFAM, TFB1M and TFB2M vari-
ants in a total of 200 HCM patients and 250 healthy
controls. The coding exons and flanking intronic se-
quences were analysed through SSCA (Fig. 1), DHPLC
(Fig. 2), and direct sequencing.
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Table 2
TFAM variants, and allele frequencies in our population. Nucleotides in
exons were numbered considering +1 as the first base in codon 1 of the
transcript (ENST00000373895). Nucleotides in introns were numbered
according to the genomic sequence (ENSG00000108064).
TFAM variants Change Allele frequencies
Patients Controls
New, exon 1 5’UTR,−91 C > A < 1% * 0
rs1937, exon 1 35 C/G, S12T C: 0.93 0.91
G: 0.07 0.09
rs17710934, exon 2 183 T/C, S61S T: 0.95 0.93
C: 0.05 0.07
rs34084383, intron 3 IVS3,−13 ins/del T Tins: 0.20 0.22
Tdel: 0.80 0.78
new, exon 4 445 G > A, A105T < 1% * 0
rs41283688, intron 6 IVS6, +12 G/A A: 0.10 0.11
G: 0.90 0.89
*These variants were found in one patient and none of the 250 controls.
Fig. 1. (A) SSCA of polymorphism rs5782396 in TFB2M, showing
the three genotypes for the IVS +26 ins/del T (intron 6). (B) SSCA of
the exon 5 fragment, showing the different electrophoretic patterns
for the 633 G/A polymorphism (rs324356).
3.1. TFAM
In the TFAM gene we identified four previously re-
ported polymorphisms (Table 2). Among the two exon
polymorphisms, rs17710934 was a silent change, and
rs1937 was the only missense variant (S12T). Allele
and genotype frequencies did not differ between pa-
tients and controls for the TFAM variants. We also
determined the haplotype frequencies and linkage dis-
equilibrium between these loci in the 150 patients and
250 controls from Spain. None of the TFAM polymor-
phisms were in significant LD, and the stimated hap-
lotype frequencies did not differ between patients and
controls (Fig. 3).
In addition to the 4 common polymorphisms, we
also found two rare TFAM variants in one patient and
none of the healthy controls. The two changes were
conserved among species. This patient was a 39 years
old male with a left ventricular septum of 17 mm and
was heterozygous for two nucleotide changes: −91
C > A in the 5’-non translated (5’-UTR) sequence
of exon 1, and a missense change in exon 4, A105T.
This patient did not have symptoms of muscular or
neurological disease. His mother was 82 years old
and had a left ventricular septum (LVS) of 19 mm.
She was heterozygous for A105T, and in this way the
patient should have the two rare variants in different
chromosomes. No other family members were affected
(the father died at the age of 60 without symptoms of
HCM).
3.2. TFB1M
In the TFB1M gene we found five previously report-
ed polymorphisms (Table 3). We also found two novel
missense variants, a G > C change in codon 120 (exon
3; A120 > P), and a G > A change in codon 189 (exon
5; G189 > R). These two changes were found in two
patients and one control and therefore regarded as rare
polymorphisms. Allele and genotype frequencies for
the five common polymorphisms did not differ between
patients and controls. The three exon 1 variants were
in complete LD (D’ = 1.0; r2 = 1.0), and in almost
complete LD with rs324356. The stimated haplotype
frequencies for each pair of loci did not differ between
patients and controls (Fig. 3).
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Table 3
TFB1M polymorphisms, and allele frequencies in our population. Nu-
cleotides in exons were numbered considering +1 as the first base in codon
1 of the transcript (ENST00000367166). Nucleotides in introns were
numbered according to the genomic sequence (ENSG00000029639).
TFB1M variants Change Allele frequencies
Patients Controls
rs1334687, exon 1 5’UTR,−75 G/T G: 0.56 0.58
T: 0.44 0.42
rs1334688, exon 1 5’UTR,−62 C/T C: 0.56 0.58
T: 0.44 0.42
rs162981, exon 1 5’UTR,−23 G/T G: 0.58 0.58
T: 0.42 0.42
New, exon 3 358 G/C, A120 > P C < 0.01 C < 0.01
New, exon 5 621 G > A, G189 > R A < 0.01 A < 0.01
rs324356, exon 5 633 G/A, T211T A: 0.42 0.42
G: 0.58 0.58
New, exon 5 631 A > G, T211 > A G < 1%* 0
New, exon 6 767 G > A, R256 > Q A < 1%* 0
T: 0.41 0.42
rs3734322, intron 6 IVS6,−30 G/T G: 0.59 0.58
* these variants were found in one patient and none of the 250 controls.
Fig. 2. DHPLC profile of the TFB1M exon 5 nucleotide variant (A631 > G), corresponding to the putative mutation Thr211 > Ala. The
PCR-amplified fragment of the heterozygous carrier eluted as two peaks, compared to the single peak in the wild-type homozygous.
Two sporadic cases had missense changes that were
not found among the 250 controls. A 35 years old
male with a LVS of 16 mm was heterozygous for a
missense change in exon 5 (631A > G; T211 > A).
A 25 years old female with a LVS of 15 mm was het-
erozygous for R256 > Q in exon 6 (767 G > A). These
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Fig. 3. Map of the TFAM, TFB1M and TFB2M showing the polymorphisms and the Linkage Disequilibrium values.
two TFB1M changes affected amino acids conserved
among species.
3.3. TFB2M
In the TFB2M gene we found a total of 11 variants
(Table 4). Three were novel polymorphisms: A64T
(exon 1, 190 G/A), IVS4 + 40 del/ins GT (intron4),
and T392T (exon 8, 1176 C/T). All the TFB2M vari-
ants were found in patients and controls, and A64 > T
was a rare polymorphism found in two patients and one
control. Allele, genotype, and haplotype frequencies
for the TFB2M variants did not differ between patients
and controls. LD analysis between pairs of loci showed
three haplotype blocks: one defined by six polymor-
phisms between rs34850511 (intron 4) and rs3124131
(intron 6) and the other by rs3129568 and rs3124119
(intron 7) (Fig. 3).
4. Discussion
MtTFA facilitates the transcription of mtDNA, and
is also important for the package of mtDNA in nu-
cleoid particles [16,18,24,25,34]. Recent studies with
transgenic mice demonstrated that mtTFA is impor-
tant to maintain the number of mtDNA-copies, and
its deletion was associated with a deficient respiratory
chain activity and symptoms of dilated cardiomyopa-
thy [42]. Moreover, this pathological phenotype was
rescued by the expression of human mtTFA in the trans-
genic mice [22]. These findings suggested that mtTFA
dysfunction could be involved in the development of
cardiac hypertrophy in humans, and TFAM gene vari-
ants could be linked to the risk for HCM. Because mt-
TFA interacts with the mitochondrial transcription fac-
tors B1 and B2, and the cellular overexpression of these
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Table 4
TFB2M polymorphisms, and allele frequencies in our population. Nu-
cleotides in exons were numbered considering +1 as the first base in codon
1 of the transcript (ENST00000366514). Nucleotides in introns were
numbered according to the genomic sequence (ENSG00000162851).
TFB2M variants Change Allele frequencies
Patients Controls
New, exon 1 190 G/A, A64T A < 0.01 A < 0.01
New, intron 4 IVS4 +40 GT Ins/Del ins: 0.98 0.95
del: 0.02 0.05
rs34850511, intron 4 IVS4 −32 A/T A: 0.57 0.55
T: 0.43 0.45
rs10754526, exon 5 723 C/T, P241P C: 0.57 0.55
T: 0.43 0.45
rs12118212, exon 5 783 A/T, K261K A: 0.57 0.55
T: 0.43 0.45
rs12037377, exon 5 790 C/T, H264Y C: 0.57 0.55
T: 0.43 0.45
rs5782396, intron 6 IVS6 +26 ins/del T insT:0.56 0.57
delT:0.44 0.43
rs3124131, intron 6 IVS6 +58 T/A T: 0.56 0.57
A: 0.44 0.43
rs3129568, exon 7 984 T/C, F328F C: 0.27 0.28
T: 0.73 0.72
rs3124119, intron 7 IVS7 +7 A/G G: 0.27 0.28
A: 0.73 0.72
New, exon 8 1176 C/T, T392T C: 0.97 0.95
T: 0.03 0.05
TFBs increases the amount of mtDNA and mitochon-
drial mass, mutations in TFB1M and TFB2M could
also influence the risk for HCM [9,12,31].
We searched for TFAM, TFB1M and TFB2M gene
variants in a cohort of HCM patients and controls. We
found several common polymorphisms, with frequen-
cies that did not differ between patients and controls,
and thus would not contribute to the risk for cardiac
hypertrophy. We also found four nucleotide changes
in three patients, but none of the healthy controls. Nu-
cleotide changes in candidate genes could be consid-
ered as putative mutations if they introduced amino
acid changes that alter protein function, affect gene ex-
pression (promoter variation), or RNA-processing (in-
tronic variants). In opposition to polymorphisms, mu-
tations are rare among healthy controls, affect amino
acids conserved among species, and segregate with the
disease in affected families. Most of the patients in
our study were sporadic cases, or from families with
a limited number of patients (not big enough to per-
form a statistically significant linkage). In this way,
the main reason to consider the two TFAM (−91 C >
A and A105 > T) and TFB1M (T211 > A and R256
> Q) as putative mutations was their absence among
the ethnically matched controls and the fact that they
were highly conserved among species. The −91 C >
A in TFAM was in a region that contains binding sites
for transcription factors such as the nuclear respiratory
factors. Amino acid 105 was in a high mobility group
(HMG) domain of mtTFA. These HGM domains show
high affinity binding for DNA sequences, and the Ala
to Thr change could affect the binding of mtTFA to
mtDNA [11,35].
Human mtTFBs are closely related to RNA adenine
methyltransferases, a group of proteins that methylate
adenine residues at a conserved stem loop of rRNA
molecules. This mtTFB dual-function as transcription
activators and rRNA modifiers represents a potential
link between transcription, ribosomal biogenesis, and
translation [39]. There are no obvious reason why the
two putative mutations in TFB1M could have a func-
tional effect, but amino acid 211 is in a beta-sheet of
the protein close to the seventh RNA methyltransferase
motif. These changes could have effects on mtTFA
and mtTFB1 expression/function, but functional stud-
ies are absolutelly necessary to confirm this point. In
contrast with these rare variants found in the patients,
the TFAM S12T alleles were frequent in patients and
controls, and this amino acid was not conserved be-
tween species (S/T in human, K in mice). In addition,
both variants would have similar mitochondrial signal
peptide characteristics, hydropathy-scores, and average
and local net charge [14].
In addition to TFB1M T211 > A and R256 > Q,
found in one patient and none of the controls, we also
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found three rare variants in two patients and one control:
A120 > P and G189 > R in TFB1M, and A64 > T
in TFB2M. Amino acids 120 and 189 of mtTFB1 are
highly conserved in mammals. However, their presence
in one healthy control suggests that they could be rare
variants not linked to HCM. The screening of more
patients and controls should be necessary to define the
association between these rare missense changes and
HCM.
Finally, in addition to describe the variation at the
TFAM, TFB1M and TFB2M in a Caucasion popula-
tion, we also reported the linkage disequilibrium be-
tween the different polymorphisms at each gene. Hap-
lotype frequencies and LD values did not differ be-
tween patients and controls, suggesting a non signifi-
cant contribution to cardiac hypertrophy. However, the
population genetics reported in our study could be use-
full for future studies with diseases in which these mi-
tochondrial transcription factors have been implicated,
such as Alzheimer’s [1].
Our work has several limitations. First, the main
argument to consider the rare variants found in the pa-
tients as putative mutations, was their absence in the
healthy controls. In addition, they affected amino acids
conserved among species, suggesting a limitation for
missense changes at these protein residues. However,
functional studies are necessary to conclude that these
variants affect the mitochondrial function. Second, the
patients who had these rare variants were sporadic cas-
es or from families with a reduced number of affect-
ed. This made impossible to stablish a familial seg-
regation of the disease with these putative mutations.
Third, the patients in our study had an essential form
of left ventricular hypertrophy, and we can not exclude
that the TFAM, TFB1M and TFB2M variants are in-
volved in the risk for hypertrophy secondary to hyper-
tension, cardiac valvular disease, exercise, or any oth-
er recognised cause of LVH. Fourth, SSCA and DH-
PLC are indirect techniques for detecting nucleotide
changes in PCR-amplified fragments, and the existence
of nucleotide changes that are not detected (approxi-
matelly 5% of false negatives) is the main limitation
for these methods. It is thus possible that some muta-
tions/polymorphisms in the mitochondrial transcription
factors were not identified in our study.
In conclusion, our work suggests that common DNA
polymorphisms at the TFAM, TFB1M and TFB2M
have no effect on risk for cardiac hypertrophy. We
found rare variants in the TFAM and TFB1M that could
contribute to the risk of developing HCM. However,
the study of larger series of patients is necessary to clar-
ify the role of mitochondrial transcription factors mu-
tations in HCM. In addition, functional studies should
be necessary to determine the biological effect of these
rare putative mutations.
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